A prospective translational trial investigating anti-PD1 with or without metformin is underway (NCT03311308) and will assess the role of decreasing tumor cell ox-phos and reversing hypoxia in the TME together with checkpoint inhibition for the treatment of advanced melanoma. Here, PDCD1 is linked to neoplasm.